Month: June 2014
-
Exclusive worldwide license agreement signed with the University of California at San Diego for two new, novel oxime drug technologies.
In the expansion of Countervail’s organophosphorus (OP) medical countermeasures, two novel oxime drug technologies were licensed from the University of California, San Diego. Similar to an existing antidote currently used, one of the acquired oxime technologies offers improved reactivation of a critical nervous system enzyme called acetylcholinesterase that is inhibited when exposed to OP toxins…
-
Countervail Corporation presents significant results of i.m. dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held in Denver Colorado.
Data funded by an SBIR grant was presented at the annual CounterACT meeting on the use of AverTox (galantamine) dosed by intramuscular injection in advance of an exposure to lethal levels of soman in guinea pigs. These data demonstrated that the use of galantamine significantly improved the survival outcomes and provided neuroprotection over the use…